Creating innovative therapies and novel delivery methods

Atossa Therapeutics is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology, with a current focus on breast cancer and radiation-induced lung injury.


Atossa regularly produces informative video content.

View Now

COVID-19 Programs

Atossa has two programs to develop therapies to treat COVID-19: One called the COVID-19 HOPE Program which uses AT-H201 for severely ill patients to improve lung function and reduce the amount of time that COVID-19 patients are on ventilators and another called AT-301 Nasal Spray for at-home use immediately following diagnosis of COVID-19 to proactively reduce symptoms of COVID-19 and to slow the infection rate so that a person’s immune system can more effectively fight the virus.

Transforming the Breast Cancer Paradigm

  • (Z)-endoxifen

    We are developing the promise of (Z)-endoxifen and exploiting its potential to both help prevent as well as to treat breast cancer with our proprietary Oral (Z) Endoxifen.

Advancing
Our Programs

We are advancing programs to help develop treatments that are effective and affordable.

Advancing
Our Programs

We are advancing programs to help develop treatments that are effective and affordable.

https://atossatherapeutics.com/wp-content/uploads/2022/10/prodcut_pipeline.png

Developing Solutions to Address all Sections of the Breast Cancer Paradigm

  • Prevention Window

  • NeoAdjuvant (Pre-surgery)

A Global Effort

We work with organizations throughout the world to move our programs forward in an efficient and cost-effective manner.

Atossa Map United States Hawaii United States Netherlands Sweden Taiwan Australia

A Global Effort

Atossa Map United States Hawaii United States Netherlands Sweden Taiwan Australia

We work with organizations throughout the world to move our programs forward in an efficient and cost-effective manner.